Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Utah Medical ProductsUTMD +0.10%73 Cash-to-Debt is 448.86 as of Jun. 2026, which is 52% above its 10-year median of 295.03. GuruFocus rates UTMD with a GF Score™ of 73/100 and a GF Value™ of $57.69 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Utah Medical Products ranks better than 92.52% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Utah Medical Products's cash to debt ratio for the quarter that ended in Jun. 2026 was 448.86.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Utah Medical Productscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Utah Medical Products's Cash-to-Debt or its related term are showing as below:
UTMD'
s Cash-to-Debt Range Over the Past 10 Years
Min: 80.65 Med: 295.03 Max: No Debt
Current: 448.86
During the past 13 years, Utah Medical Products's highest Cash to Debt Ratio was No Debt. The lowest was 80.65. And the median was 295.03.
UTMD's Cash-to-Debt is ranked better than 92.52% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs UTMD: 448.86
Utah Medical Products (NAS:UTMD) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Utah Medical Products Cash-to-Debt Related Terms
Utah Medical Products Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Utah Medical Products's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Utah Medical Products's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Utah Medical Products Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Utah Medical Products's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Utah Medical Products's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Utah Medical Products (UTMD) has a Cash-to-Debt of 448.86 as of Jun. 2026. This is 52% above median its historical median of 295.03. Over the past decade, Utah Medical Products' Cash-to-Debt has ranged from 80.65 to 10,000.00. According to the industry distribution chart, Utah Medical Products ranks #63 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 7.5%.
Is Utah Medical Products' Cash-to-Debt too high?
Utah Medical Products' current Cash-to-Debt of 448.86 is 52% above median its 10-year median of 295.03. Over the past 10 years, this metric has ranged from a low of 80.65 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Utah Medical Products' value of 448.86 is 27353.2% above this industry median. Based on the distribution chart, Utah Medical Products ranks #63 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Utah Medical Products has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Utah Medical Products' Cash-to-Debt compare to OSUR and PDEX?
According to the Medical Devices & Instruments industry distribution chart, Utah Medical Products ranks #63 out of 842 companies for Cash-to-Debt. This places Utah Medical Products in the top 8% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.64. Utah Medical Products' value of 448.86 is 27353.2% above this benchmark. Historically, Utah Medical Products' own Cash-to-Debt has ranged from 80.65 to 10,000.00 over the past decade. While the company's 10-year median is 295.03 vs. the industry median of 1.64, Utah Medical Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Utah Medical Products's current Cash-to-Debt of 448.86 is 27353.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Utah Medical Products's current Cash-to-Debt is 448.86, which is 52% above median its own 10-year median of 295.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Utah Medical Products stock overvalued right now?
Based on GuruFocus' analysis, Utah Medical Products (UTMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $57.69, compared to a current price of $69.73 — trading 20.9% above its estimated fair value. The current Cash-to-Debt is 448.86, which is 52% above median its 10-year median of 295.03 and 27353.2% above the Medical Devices & Instruments industry median of 1.64. Utah Medical Products' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Utah Medical Products (UTMD), the current Cash-to-Debt is 448.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Utah Medical Products (UTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Utah Medical Products stock appears to be overvalued.
The current stock price of $69.73 is trading 20.9% above its estimated GF Value™ of $57.69.
GuruFocus considers Utah Medical Products to be Modestly Overvalued.
Key valuation signals for UTMD:
Cash-to-Debt: 448.86 (52% above median its 10-year median of 295.03)
GF Value™: $57.69 vs. price of $69.73 (20.9% above fair value)
Industry Position: 27353.2% above the Medical Devices & Instruments median (#63 of 842)
No single metric tells the full story. See the UTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
73GF Score
Get the complete analysis for UTMD
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTMD has been successfully added to your 
